This website is for US healthcare professionals only. This website is not intended for patients.

Logo Horizontal
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
Compare drug alternatives

Aimovig® Alternatives

Aimovig®

(Erenumab)
Aimovig
    Migraine
  • Emgality®
  • Vyepti®
  • Nurtec ODT®
  • Ubrelvy®
  • Qulipta®
Prescription Only
Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site reactions and constipation. However, there are no reported instances of drug interactions with Aimovig. Aimovig is FDA approved for the following indications: Migraine prevention.

Ajovy®

(Fremanezumab)
Ajovy
    Migraine
  • Emgality®
  • Vyepti®
  • Nurtec ODT®
  • Ubrelvy®
  • Qulipta®
Prescription Only
Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side effect is injection site reactions. Ajovy does not seem to cause constipation. Additionally, there are no known drug interactions. Ajovy is FDA approved for the following indications: Migraine prevention.

Dosage & Administration

Administration
Subcutaneous
Subcutaneous
Dosing
70 mg once monthly or 140 mg once monthly (for some patients)
225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each)
Latin Shorthand
70 mg/mo or 140 mg/mo
225 mg/mo or 675 mg q3mo

Financial Assistance

Copay
$5
$5
Annual Cap
Patient specific maximum benefit.
Patient specific maximum benefit.
Assistance Expiration
Calendar year
12/31/2023
Generics
No lower-cost generic available
No lower-cost generic available

Popular alternatives

  • Aimovig® vs. Emgality®
  • Aimovig® vs. Vyepti®
  • Aimovig® vs. Nurtec odt®
  • Aimovig® vs. Ubrelvy®
  • Aimovig® vs. Qulipta®

Relevant Resources

Aimovig
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Ajovy
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Company
About
Careers
Privacy
Terms
Contact
Solutions
Prescribing Information
Coverage Restrictions
Prior Authorization
Financial Assistance
Sample Requests
Practice Collaboration
Rep Management
Indications
Most Viewed
Angioedema
Atopic Dermatitis
Plaque Psoriasis
Psoriatic Arthritis
Rosacea
Compare drug alternatives
Providers
Log in
Sign up
Request demo
© PrescriberPoint, Inc. 2023. Help Patients, Increase Practice Efficiency.